Research Study

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Principal Investigator 
James Lan

Overview

Body Locations and Systems 
Kidney Disease
Diagnosis and Therapy 
Kidney Transplantation
ClinicalTrials.gov# 
NCT03443869
Status 
Recruiting
Study Start/End 
Dec 5, 2018 to Sep 19, 2021
Locations 
Vancouver General Hospital
Name/Title 
Angela Ogniben, Research Coordinator
Phone 
604-682-2344 ext.64707
Purpose of Study 

The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.